Rhenman & Partners Asset Management Ab Iovance Biotherapeutics, Inc. Transaction History

Rhenman & Partners Asset Management Ab

$1.2 Billion
Q3 2024

A detailed history of Rhenman & Partners Asset Management Ab transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 1,052,500 shares of IOVA stock, worth $8.57 Million. This represents 0.82% of its overall portfolio holdings.

Number of Shares

1,052,500

Previous 920,000 14.4%

Holding current value

$8.57 Million

Previous $7.38 Million 33.94%

% of portfolio

0.82%

Previous 0.73%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$7.28 - $11.9 $964,600 - $1.58 Million	132,500 Added 14.4%	1,052,500 $9.88 Million
Q2 2024 Aug 13, 2024	SELL	$7.78 - $14.19 $272,300 - $496,650	-35,000 Reduced 3.66%	920,000 $7.38 Million
Q1 2024 May 14, 2024	SELL	$7.59 - $17.47 $1.23 Million - $2.83 Million	-161,818 Reduced 14.49%	955,000 $14.2 Million
Q4 2023 Feb 13, 2024	BUY	$3.3 - $8.89 $550,499 - $1.48 Million	166,818 Added 17.56%	1,116,818 $9.08 Million
Q3 2023 Nov 13, 2023	BUY	$4.44 - $8.79 $4.06 Million - $8.04 Million	915,000 Added 2614.29%	950,000 $4.32 Million
Q3 2023 Nov 09, 2023	SELL	$4.44 - $8.79 $3.62 Million - $7.16 Million	-815,000 Reduced 95.88%	35,000 $159,000
Q2 2023 Aug 11, 2023	BUY	$5.36 - $9.06 $878,128 - $1.48 Million	163,830 Added 23.88%	850,000 $5.98 Million
Q1 2023 May 11, 2023	SELL	$5.53 - $8.22 $985,490 - $1.46 Million	-178,208 Reduced 20.62%	686,170 $4.19 Million
Q4 2022 Feb 13, 2023	BUY	$5.62 - $10.0 $1.99 Million - $3.54 Million	354,378 Added 69.49%	864,378 $5.52 Million
Q3 2022 Nov 14, 2022	SELL	$9.53 - $13.11 $190,600 - $262,200	-20,000 Reduced 3.77%	510,000 $4.76 Million
Q2 2022 Aug 12, 2022	BUY	$6.38 - $18.33 $350,900 - $1.01 Million	55,000 Added 11.58%	530,000 $5.85 Million
Q1 2022 May 13, 2022	SELL	$12.38 - $19.1 $1.55 Million - $2.39 Million	-125,000 Reduced 20.83%	475,000 $7.91 Million
Q4 2021 Feb 11, 2022	BUY	$16.55 - $27.63 $4.63 Million - $7.74 Million	280,000 Added 87.5%	600,000 $11.7 Million
Q3 2021 Nov 12, 2021	BUY	$20.35 - $26.63 $407,000 - $532,600	20,000 Added 6.67%	320,000 $7.89 Million
Q2 2021 Aug 13, 2021	BUY	$16.33 - $33.07 $81,649 - $165,350	5,000 Added 1.69%	300,000 $7.81 Million
Q1 2021 May 14, 2021	SELL	$28.67 - $52.59 $716,750 - $1.31 Million	-25,000 Reduced 7.81%	295,000 $9.34 Million
Q4 2020 Jan 19, 2021	SELL	$28.04 - $50.26 $560,800 - $1.01 Million	-20,000 Reduced 5.88%	320,000 $14.8 Million
Q2 2020 Jul 16, 2020	SELL	$27.21 - $41.0 $680,250 - $1.03 Million	-25,000 Reduced 6.85%	340,000 $9.33 Million
Q1 2020 Apr 16, 2020	SELL	$19.54 - $38.85 $2.15 Million - $4.27 Million	-110,000 Reduced 23.16%	365,000 $10.9 Million
Q4 2019 Jan 17, 2020	SELL	$17.95 - $29.41 $807,750 - $1.32 Million	-45,000 Reduced 8.65%	475,000 $13.1 Million
Q3 2019 Oct 16, 2019	SELL	$17.99 - $26.0 $4.15 Million - $6 Million	-230,700 Reduced 30.73%	520,000 $9.46 Million
Q2 2019 Jul 22, 2019	SELL	$9.78 - $24.52 $1.26 Million - $3.16 Million	-128,900 Reduced 14.65%	750,700 $18.4 Million
Q1 2019 Apr 11, 2019	SELL	$8.41 - $11.26 $2.74 Million - $3.67 Million	-325,895 Reduced 27.03%	879,600 $8.37 Million
Q4 2018 Feb 05, 2019	SELL	$7.51 - $11.93 $638,350 - $1.01 Million	-85,000 Reduced 6.59%	1,205,495 $10.7 Million
Q3 2018 Oct 03, 2018	BUY	$11.25 - $17.7 $4.98 Million - $7.84 Million	443,019 Added 52.28%	1,290,495 $14.5 Million
Q2 2018 Jul 20, 2018	SELL	$12.45 - $16.95 $1.2 Million - $1.64 Million	-96,709 Reduced 10.24%	847,476 $10.8 Million
Q4 2017 Jan 19, 2018	BUY	$6.65 - $9.25 $1.55 Million - $2.16 Million	233,022 Added 32.77%	944,185 $7.55 Million
Q3 2017 Oct 13, 2017	BUY	$4.45 - $8.55 $3.16 Million - $6.08 Million	711,163	711,163 $5.51 Million

Others Institutions Holding IOVA

# of Institutions

313

Shares Held

241M

Call Options Held

3.77M

Put Options Held

1.7M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.28B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account

Rhenman & Partners Asset Management Ab Iovance Biotherapeutics, Inc. Transaction History